Avenzo takes a second shot at CDK-selective inhibition
AVZO-023 follows AVZO-021 into clinical trials.
Kura joins the pivotal menin push
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
AbbVie's telisotuzumab conjugate take two
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
A bispecific encore, plus two in vivo Cars
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
ASCO 2025 movers – bispecifics to the rescue
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Werner not good enough for Roche
Roche dumps another partnered asset.
ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
